Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Average Price Target from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $25.60.

ATXS has been the subject of a number of recent analyst reports. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, December 10th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of Astria Therapeutics by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 2,556 shares during the period. Quest Partners LLC boosted its holdings in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares in the last quarter. Bank of New York Mellon Corp grew its position in Astria Therapeutics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 8,965 shares during the period. Wellington Management Group LLP increased its holdings in Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 11,763 shares in the last quarter. Finally, PDT Partners LLC acquired a new position in shares of Astria Therapeutics in the third quarter worth about $140,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Up 0.2 %

Shares of ATXS opened at $9.54 on Thursday. The company has a 50 day moving average of $10.54 and a two-hundred day moving average of $10.72. Astria Therapeutics has a twelve month low of $6.58 and a twelve month high of $16.90. The company has a market cap of $538.38 million, a price-to-earnings ratio of -4.56 and a beta of 0.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.